Mario Scuri
Parma, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Inspiratory flow profile and usability of the NEXThaler, a multidose dry powder inhaler, in asthma and COPD.
Journal: BMC pulmonary medicine
Published: November 02, 2020
Validity and responsiveness of the Daily- and Clinical visit-PROactive Physical Activity in COPD (D-PPAC and C-PPAC) instruments.
Journal: Thorax
Published: January 14, 2020
Inhaled corticosteroid containing combinations and mortality in COPD.
Journal: The European respiratory journal
Published: July 02, 2018
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
Journal: Lancet (London, England)
Published: January 11, 2018
Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
Journal: International journal of chronic obstructive pulmonary disease
Published: October 25, 2017
Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study.
Journal: International journal of chronic obstructive pulmonary disease
Published: July 27, 2017
Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study.
Journal: Pulmonary pharmacology & therapeutics
Published: November 04, 2016
Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
Journal: Lancet (London, England)
Published: October 28, 2016
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
Journal: Lancet (London, England)
Published: June 30, 2016
High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids.
Journal: BMC pulmonary medicine
Published: March 07, 2016
Inhaled beclometasone dipropionate/formoterol fumarate extrafine fixed combination for the treatment of asthma.
Journal: Expert review of respiratory medicine
Published: March 04, 2016
Pharmacokinetics and pharmacodynamics of an extrafine fixed pMDI combination of beclometasone dipropionate/formoterol fumarate in adolescent asthma.
Journal: British journal of clinical pharmacology
Published: December 12, 2014
Last Updated: 09/26/2026